ArticleAmerican journal of respiratory and critical care medicine2018
Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.
Article in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Immune Checkpoint Inhibitors in Cancer Patients With Concurrent Active Tuberculosis: A Real-World Study in a High Tuberculosis Burden Region.Open forum infectious diseases · 2026Article
- Immune endotypes in tuberculosis: Keys to decoding disease complexity.Journal of internal medicine · 2026Review
- A co-evolutionary perspective on humans andeLife · 2026Review
- Immune checkpoint inhibitors in infectious diseases: therapeutic reinvigoration, immunopathology, and precision targeting.Frontiers in immunology · 2026Review
- Immunotherapy for tuberculosis: current landscape, mechanistic insights, and translational perspectives.Frontiers in immunology · 2026Review
- Lung squamous cell carcinoma complicated with immune checkpoint inhibitor-associated active tuberculosis: a case report and literature review.Frontiers in oncology · 2026Article
- A Case of Advanced Urothelial Carcinoma Requiring Treatment Following a Positive Interferon-Gamma Release Assay Prior to Avelumab Administration.IJU case reports · 2025Article
- Characterization of Early Lesions of Human Post-Primary Tuberculosis and Its Progression to Necrosis Using Archival Material of the Pre-Antibiotic Era.Pathogens (Basel, Switzerland) · 2025Article
- A Simultaneous Presentation of Nasopharyngeal Carcinoma and Latent Cervical Tuberculosis: Insights into a Complex Case.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Leveraging insights from cancer to improve tuberculosis therapy.Trends in molecular medicine · 2025Article
- Screening and treatment of latent tuberculosis in patients with solid tumors and systemic cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Open questions between immune checkpoint inhibitors and tuberculosis incidence.Journal of thoracic disease · 2024Article
- The controversy of immune checkpoint inhibition and risk of mycobacterial infections: the need for further studies and continued discussions on this puzzling issue.Journal of thoracic disease · 2024Article
- Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.BMC pulmonary medicine · 2024Article
- Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy.The oncologist · 2024Article
- A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?Journal of thoracic disease · 2024Review
- Article
- Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.